FDA Drug Safety Overhaul Will Not Affect Oncologics, Office Director Says
Executive Summary
Potential changes to FDA's safety review practices will not affect oncology therapies, Office of Oncology Drug Products Director Richard Pazdur said at the American Society of Clinical Oncology annual meeting in Orlando, Fla. May 14